Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals.
Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.
“The world needs tenacious healthcare founders now more than ever. Patients’ lives will be permanently better off because these teams are just crazy enough to be up for the task.”